Abstract
Acquisition of resistance to the cytotoxic effects of anticancer agents is one of the most significant impediments to effective cancer therapy. Although various cancer-cell intrinsic mechanisms of drug resistance have been identified, chemotherapy resistance remains one of the major causes of cancer patient death. Emerging evidence suggests that the inflammatory tumor-microenvironment plays an important additional role in modulating drug responsiveness and drug resistance; however, underlying mechanisms are still largely unknown. In this review, we discuss data supporting the idea that crosstalk between components of the immune system and cancer cells can influence chemoresistance, and we will speculate on possible underlying pathways and clinical implications. A deeper understanding of the cancer cell-intrinsic and – extrinsic mechanisms of drug resistance will accelerate the development of novel combinatorial anticancer therapies in which drug resistance is prevented or reversed.
Keywords: Cancer, inflammation, chemoresistance, microenvironment, chemotherapy
Current Pharmaceutical Design
Title: Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance
Volume: 15 Issue: 16
Author(s): Karin E. de Visser and Jos Jonkers
Affiliation:
Keywords: Cancer, inflammation, chemoresistance, microenvironment, chemotherapy
Abstract: Acquisition of resistance to the cytotoxic effects of anticancer agents is one of the most significant impediments to effective cancer therapy. Although various cancer-cell intrinsic mechanisms of drug resistance have been identified, chemotherapy resistance remains one of the major causes of cancer patient death. Emerging evidence suggests that the inflammatory tumor-microenvironment plays an important additional role in modulating drug responsiveness and drug resistance; however, underlying mechanisms are still largely unknown. In this review, we discuss data supporting the idea that crosstalk between components of the immune system and cancer cells can influence chemoresistance, and we will speculate on possible underlying pathways and clinical implications. A deeper understanding of the cancer cell-intrinsic and – extrinsic mechanisms of drug resistance will accelerate the development of novel combinatorial anticancer therapies in which drug resistance is prevented or reversed.
Export Options
About this article
Cite this article as:
de Visser E. Karin and Jonkers Jos, Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance, Current Pharmaceutical Design 2009; 15 (16) . https://dx.doi.org/10.2174/138161209788453239
DOI https://dx.doi.org/10.2174/138161209788453239 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial from Guest Editor: [Hot Topic: The Role of the Surgeon in Managing Pleural Based Diseases]
Current Respiratory Medicine Reviews Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
Current Medicinal Chemistry Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells
Current Drug Targets Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets Antifolates - Past, Present and Future
Current Medicinal Chemistry - Anti-Cancer Agents Modifications of Cell Signalling and Redox Balance by Targeting Protein Acetylation Using Natural and Engineered Molecules: Implications in Cancer Therapy
Current Topics in Medicinal Chemistry Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery PPSu-PEG Copolymers and their Application in the Preparation of Cisplatin-loaded Nanoparticles
Current Nanoscience Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Proteomics Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Mapping the Technological Knowledge Landscape: The Case of Epigenetics
Recent Patents on Anti-Cancer Drug Discovery Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus
Current Cancer Drug Targets Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry The Beneficial Effects of Sulfur-containing Amino Acids on Cisplatininduced Cardiotoxicity and Neurotoxicity in Rodents
Current Medicinal Chemistry Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Antisense Treatment in Human Prostate Cancer and Melanoma
Current Cancer Drug Targets Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry